Literature DB >> 22495122

Dynamics of the antibodies in cohorts of cured cases of visceral leishmaniasis: its implication on the validity of serological test, value in prognosis and in post therapeutic assessment.

Rajan R Patil1, Jayaparakash P Muliyil, A Nandy, A Addy, A K Maji, Prabir Chatterjee.   

Abstract

The major disadvantage of a Serological test like Direct Agglutination Test (DAT) for Visceral Leishmaniasis (also called Kala-azar) is its inability to distinguish between recent and past infection. The objective of our study was to look at rate of decline of antibodies in fully cured cases of Kala-azar and length of time it takes for DAT to become negative. Cohort Study involving completely treated Kala-azar cases from Government Hospital during one calendar year of study. Cases were selected on the basis of treatment cohorts 0, 3, 6, 9 & 12 mo after completion of treatment.. Phase I--The cases were traced and after obtaining the informed consent they were subjected to Direct Agglutination Test (DAT). Phase II--The five treatment cohorts, constituting 82 cured cases (average of 15 cured cases per each treatment cohort) were tested again with DAT three months after the first test. The titers of Phase-I and phase-II tests were analyzed for the dynamics of the antibodies for the period. Cutoff-Values of DAT below 1:800 are considered negative. Values of 1:800, 1:1200, 1:1600 and so on are considered positive. The mean titer [Geometric Mean Titer (GMT)] at the start of treatment was 1:1120, which showed steady decline up to six months, plummeting below the cutoff titer for the DAT (1:800) at the ninth month. Antibodies continue to linger for about one year in cured Kala-azar cases even after correct and complete treatment. Single DAT results may be misleading due to high false positivity up to one year after the cure. Paired test defined as two tests 3 mo apart on the same subject. Paired test is highly recommended for diagnosis and prognosis. DAT is still a very useful tool for diagnosis if used along with clinical correlation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495122     DOI: 10.4161/hv.19542

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  8 in total

1.  Correlation of Rk39-Specific Antibodies and Thyroid Function in Patients with Visceral Leishmaniasis.

Authors:  Ali Ibrahim Ali Al-Ezzy; Walaa Najm Abood
Journal:  Eurasian J Med       Date:  2016-10

2.  Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.

Authors:  A C Vallur; A Hailu; D Mondal; C Reinhart; H Wondimu; Y Tutterrow; H W Ghalib; S G Reed; M S Duthie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-19       Impact factor: 3.267

3.  IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test.

Authors:  Tapan Bhattacharyya; Armon Ayandeh; Andrew K Falconar; Shyam Sundar; Sayda El-Safi; Marissa A Gripenberg; Duncan E Bowes; Caroline Thunissen; Om Prakash Singh; Rajiv Kumar; Osman Ahmed; Osama Eisa; Alfarazdeg Saad; Sara Silva Pereira; Marleen Boelaert; Pascal Mertens; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 4.  Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: A review and analysis of data from diagnostic and epidemiological studies.

Authors:  Lloyd A C Chapman; Alex L K Morgan; Emily R Adams; Caryn Bern; Graham F Medley; T Déirdre Hollingsworth
Journal:  PLoS Negl Trop Dis       Date:  2018-12-06

5.  Detection of Immunoglobulin G1 Against rK39 Improves Monitoring of Treatment Outcomes in Visceral Leishmaniasis.

Authors:  Guy Mollett; Bruno C Bremer Hinckel; Tapan Bhattacharyya; Tegwen Marlais; Om Prakash Singh; Pascal Mertens; Andrew K Falconar; Sayda El-Safi; Shyam Sundar; Michael A Miles
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

6.  Frequency of Leishmania spp. infection among HIV-infected patients living in an urban area in Brazil: a cross-sectional study.

Authors:  M A Cunha; B J Celeste; N Kesper; M Fugimori; M M Lago; A S Ibanes; L M Ouki; E A Simões Neto; F F Fonseca; M A L Silva; W L Barbosa Júnior; J A L Lindoso
Journal:  BMC Infect Dis       Date:  2020-11-25       Impact factor: 3.090

Review 7.  Immunodiagnosis of Visceral Leishmaniasis: Current Status and Challenges: A Review Article.

Authors:  Bahador Sarkari; Zahra Rezaei; Mehdi Mohebali
Journal:  Iran J Parasitol       Date:  2018 Jul-Sep       Impact factor: 1.012

8.  Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis.

Authors:  Bruno Cesar Bremer Hinckel; Tegwen Marlais; Stephanie Airs; Tapan Bhattacharyya; Hideo Imamura; Jean-Claude Dujardin; Sayda El-Safi; Om Prakash Singh; Shyam Sundar; Andrew Keith Falconar; Bjorn Andersson; Sergey Litvinov; Michael A Miles; Pascal Mertens
Journal:  PLoS Negl Trop Dis       Date:  2019-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.